Home › BODALCHEM › Filing
🔔 Get instant alerts when BODALCHEM files quarterly results on BSE Start free trial →

Investor Presentation

Filed: 03 Nov 2026, 14:58 IST Exchange: NSE Category: Financial Results — Investor Presentation
AI summary - H1FY27 consolidated revenue Rs 15,991 mn +67% y-y; Q2FY27 Rs 8,840 mn +77% y-y - H1FY27 EBITDA Rs 2,027 mn +114% y-y; Q2FY27 EBITDA Rs 1,276 mn +197% y-y; margins improved to 12.7% H1, 14.4% Q2 - H1FY27 PAT Rs 1,118 mn +620% y-y; Q2FY27 PAT Rs 814 mn +1259% y-y - Dye intermediates revenue grew 68% H1FY27; Basic chemicals up 136% y-y; Chlor alkali up 6% y-y - Subsidiaries BCTPL and Bodal China showed strong growth; Sener Boya stable - Management expects continued strong performance due to China structural changes and benzene downstream plant stabilization - Net debt/equity improved to 0.67x in FY26; ROE 4.1% FY26 - Capacity ~470,000 MTPA with ongoing expansions and integrated manufacturing - Company focuses on backward integration, cost competitiveness, and international market expansion
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 BODALCHEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add BODALCHEM to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Bodal Chemicals Limited

Important. The summary above is generated automatically from Bodal Chemicals Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.